# Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

> **NCT03360721** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Castration-Resistant Prostate Carcinoma
- Prostate Adenocarcinoma Without Neuroendocrine Differentiation
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Abiraterone Acetate
- **DRUG:** Apalutamide
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT03360721
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-06
- **Primary completion:** 2026-03-12
- **Final completion:** 2026-03-12
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** \<75% participation
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03360721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03360721, "Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03360721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*